129 TSPO expression in healthy and diseased brain 1. Guilarte TR. TSPO in diverse CNS pathologies and psychiatric disease: A critical review and a way forward. Pharmacol Ther. Feb 2019;194:44-58. doi:10.1016/j.pharmthera.2018.09.003 2. Venneti S, et al. PK11195 labels activated microglia in Alzheimer’s disease and in vivo in a mouse model using PET. Neurobiol Aging. Aug 2009;30(8):121726. doi:10.1016/j.neurobiolaging.2007.11.005 3. Gui Y, et al. Characterization of the 18 kDa translocator protein (TSPO) expression in postmortem normal and Alzheimer’s disease brains. Brain Pathol. Jan 2020;30(1):151-164. doi:10.1111/ bpa.12763 4. Kaunzner UW, et al. Quantitative susceptibility mapping identifies inflammation in a subset of chronic multiple sclerosis lesions. Brain. Jan 1 2019;142(1):133-145. doi:10.1093/brain/awy296 5. Maeda J, et al. In vivo positron emission tomographic imaging of glial responses to amyloidbeta and tau pathologies in mouse models of Alzheimer’s disease and related disorders. J Neurosci. Mar 23 2011;31(12):4720-30. doi:10.1523/JNEUROSCI.3076-10.2011 6. Nutma E, et al. A quantitative neuropathological assessment of translocator protein expression in multiple sclerosis. Brain. Nov 1 2019;142(11):34403455. doi:10.1093/brain/awz287 7. Ahmad R, et al. Whole-body biodistribution and radiation dosimetry of the cannabinoid type 2 receptor ligand [11C]-NE40 in healthy subjects. Mol Imaging Biol. Aug 2013;15(4):384-90. doi:10.1007/ s11307-013-0626-y 8. Attili B, et al. Preclinical evaluation of [(18) F] MA3: a CB2 receptor agonist radiotracer for PET. Br J Pharmacol. May 2019;176(10):1481-1491. doi:10.1111/bph.14564 9. Kumar JSD, et al. Radiosynthesis and evaluation of [(18)F]FMTP, a COX-2 PET ligand. Pharmacol Rep. Oct 2020;72(5):1433-1440. doi:10.1007/s43440020-00124-z 10. Shrestha S, et al. PET measurement of cyclooxygenase-2 using a novel radioligand: upregulation in primate neuroinflammation and first-in-human study. J Neuroinflammation. May 2 2020;17(1):140. doi:10.1186/s12974-020-01804-6 11. Hosoya T, et al. In vivo TSPO and cannabinoid receptor type 2 availability early in post-stroke neuroinflammation in rats: a positron emission tomography study. J Neuroinflammation. Mar 29 2017;14(1):69. doi:10.1186/s12974-017-0851-4 12. Pottier G, et al. PET imaging of cannabinoid type 2 receptors with [(11)C]A-836339 did not evidence changes following neuroinflammation in rats. J Cereb Blood Flow Metab. Mar 2017;37(3):11631178. doi:10.1177/0271678X16685105 13. Territo PR, et al. Characterization of (11) C-GSK1482160 for Targeting the P2X7 Receptor as a Biomarker for Neuroinflammation. J Nucl Med. Mar 2017;58(3):458-465. doi:10.2967/ jnumed.116.181354 14. Berdyyeva T, et al. PET Imaging of the P2X7 Ion Channel with a Novel Tracer [(18)F]JNJ-64413739 in a Rat Model of Neuroinflammation. Mol Imaging Biol. Oct 2019;21(5):871-878. doi:10.1007/s11307018-01313-2 15. Kolb HC, et al. Preclinical Evaluation and Nonhuman Primate Receptor Occupancy Study of (18) F-JNJ-64413739, a PET Radioligand for P2X7 Receptors. J Nucl Med. Aug 2019;60(8):1154-1159. doi:10.2967/jnumed.118.212696 16. Liu H, et al. PET Imaging Study of S1PR1 Expression in a Rat Model of Multiple Sclerosis. Mol Imaging Biol. Oct 2016;18(5):724-32. doi:10.1007/s11307016-0944-y 17. Weng CC, et al. Correlation analysis of [(18) F]ROStrace using ex vivo autoradiography and dihydroethidium fluorescent imaging in lipopolysaccharide-treated animals. Biochem Biophys Res Commun. Aug 20 2019;516(2):397401. doi:10.1016/j.bbrc.2019.06.062 18. Horti AG, et al. PET imaging of microglia by targeting macrophage colony-stimulating factor 1 receptor (CSF1R). Proc Natl Acad Sci U S A. Jan 29 2019;116(5):1686-1691. doi:10.1073/ pnas.1812155116 19. Papadopoulos V, et al. Translocator protein (18kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol Sci. Aug 2006;27(8):402-9. doi:10.1016/j.tips.2006.06.005 20. Rupprecht R, et al. Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders. Nat Rev Drug Discov. Dec 2010;9(12):971-88. doi:10.1038/nrd3295 21. VeenmanL,etal.Channel-likefunctionsofthe18-kDa translocator protein (TSPO): regulation of apoptosis and steroidogenesis as part of the host-defense response. Curr Pharm Des. 2007;13(23):2385-405. doi:10.2174/138161207781368710 22. Gavish M, et al. Enigma of the peripheral benzodiazepine receptor. Pharmacol Rev. Dec 1999;51(4):629-50. 23. Austin CJ, et al. The translocator protein (TSPO): a novel target for cancer chemotherapy. Int J Biochem Cell Biol. Jul 2013;45(7):1212-6. doi:10.1016/j. biocel.2013.03.004 24. Batarseh A, et al. Regulation of translocator protein 18 kDa (TSPO) expression in health and disease states. Mol Cell Endocrinol. Oct 7 2010;327(1-2):112. doi:10.1016/j.mce.2010.06.013 25. Caballero B, et al. Role of mitochondrial translocator protein (18 kDa) on mitochondrial- related cell death processes. Recent Pat Endocr Metab Immune Drug Discov. May 2013;7(2):86References
RkJQdWJsaXNoZXIy MTk4NDMw